Browsing by Subject "Remission Induction"

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Cyclic lymphocytic vasculitis associated with chronic lymphocytic leukemia
    (2004) Çabuk M.; Inanir I.; Türkdoǧan P.; Ceylan C.; Deǧirmenci M.; Türel A.; Özdemir E.
    Lymphocytic cutaneous vasculitis associated with a haematological malignancy has rarely been reported. Here, we describe a 61 year-old woman with chronic lymphocytic leukemia (CLL) who presented with cutaneous lesions on both hands. These lesions improved after all combination chemotherapy courses and recurred before each course. Repetitive skin biopsies revealed lymphocytic vasculitis. After 7 courses of chemotherapy, she had a complete remission. Skin lesions disappeared and did not recur. The cyclic pattern of lymphocytic vasculitis and its relation with CLL disease activity are interesting clinical features in this case. © 2004 Taylor & Francis Ltd.
  • No Thumbnail Available
    Item
    Magnetic resonance imaging findings in a case of remitting seronegative symmetrical synovitis with pitting edema
    (2005) Unlu Z.; Orguc S.; Ovali G.Y.; Tarhan S.; Dayan I.; Angin A.
    We describe a case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome) in a 66-year-old man. This report discusses magnetic resonance imaging findings of RS3PE syndrome and the changes after steroid therapy. © Clinical Rheumatology 2005.
  • No Thumbnail Available
    Item
    Brucellosis: A rare cause of febrile neutropenia in acute myeloblastic leukemia
    (2011) Ozbalci D.; Ergene U.; Cetin C.B.
    Brucellosis is a zoonotic disease and endemically seen in the Middle East, Eastern Europe and continental America. Febrile neutropenia related to Brucellosis has been reported only in a few cases. Brucella was cultured from the bone morrow of a 42-year-old woman who was admitted to hospital with symptoms of fever and fatigue and later diagnosed as acute myeloblastic leukemia (AML). The patient was treated for both AML and Brucellosis without any problems and discharged from the hospital after scheduling her follow-up visits. Brucellosis might be considered in the etiology of febrile neutropenia in endemic regions and must be treated effectively to prevent possible morbidity and mortality during or after chemotherapy. © 2010 Springer Science+Business Media, LLC.
  • No Thumbnail Available
    Item
    Coexistence of psoriasis and bullous pemphigoid: Remission with low-dose methotrexate
    (2013) Gunay U.; Gunduz K.; Türel Ermertcan A.; Kandiloǧlu A.Ri.
    The coexistence of psoriasis vulgaris and bullous pemphigoid is rare. Here, we report a 90-year-old patient with a 20-year history of psoriasis. She developed vesicles and bullae suddenly and was diagnosed as bullous pemphigoid. Low-dose methotrexate therapy quickly cleared both psoriatic and bullous lesions. © 2013 Informa Healthcare USA, Inc.
  • No Thumbnail Available
    Item
    Comparison of 18F-FDG PET/CT findings with current clinical disease status in patients with takayasu's arteritis
    (2013) Karapolat I.; Kalfa M.; Keser G.; Yalçin M.; Inal V.; Kumanlioǧlu K.; Pirildar T.; Aksu K.
    Objective. 18F-fluorodeoxyglucosepositron emission tomography/computed tomography (18F-FDG PET/CT) scanning has been proposed as a new tool to assess disease activity in Takayasu arteritis (TA). We investigated whether 18F-FDG PET/CT findings were consistent with current clinical disease status in patients with TA. Methods. In this cross sectional study, 22 patients with TA were enrolled. Clinical disease activity was assessed by the combination of National Institutes of Health (NIH) criteria, Disease Extent Index-Takayasu (DEI-Tak) score, physician global assessment and 18F-FDG PET/CT scans. Results. At the time 18F-FDG PET/CT scans were taken, the majority of the patients (17/22) were using immunosuppressive (IS) drugs, and only four patients had clinically active disease. 18F-FDG PET/CT scans confirmed the presence of active vasculitic lesions in those four patients. In 16 out of 18 patients who were accepted to be in clinical remission, 18F-FDG PET/ CT scans were also normal. There were only two patients with discordant results, i.e. active 18F-FDG PET/CT findings despite the lack of clinical activity. Interestingly, clinical exacerbation occurred four weeks later in one of them. Overall sensitivity and specificity of 18F-FDG PET/CT findings for clinical activity were 100% and 88.9%, respectively. Conclusion. We found that 18F-FDG PET/CT findings were generally consistent with clinical disease status in TA. Although use of IS drugs certainly impairs diagnostic accuracy of 18FFDG PET/CT in TA, this imaging method may still have a potential for confirming remission or detecting disease activity in patients with TA receiving treatment. © CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2013.
  • No Thumbnail Available
    Item
    Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study
    (Blackwell Publishing Ltd, 2018) Aksoy B.; Hapa A.; Mutlu E.
    Background: The literature includes only a few reports of oral isotretinoin for the treatment of folliculitis decalvans (FD). This study aimed to determine the most effective dose and duration of oral isotretinoin monotherapy for achieving remission in FD patients. Methods: This retrospective case series study included FD patients that were treated with oral isotretinoin. Patient demographics, clinical characteristics, and treatment details were obtained from the patients’ medical records. Patients were contacted via telephone after treatment was completed and asked about any relapses, time period of relapses, and the long-term effects of the treatment. Results: The study included 39 male patients with a mean age of 37.9 ± 15.5 years. All of the patients received oral isotretinoin 0.1–1.02 mg/kg/day (10–90 mg/day) for a median duration of 2.5 months (range: 1–8 months). In all, 82.0% of patients healed after the treatment. Patients that received oral isotretinoin ≥0.4 mg/kg/day for ≥3 months responded better, and 66% of them never relapsed. Conclusion: Contrary to general belief, oral isotretinoin monotherapy resulted in complete response in the majority of patients in this study. Based on this finding, we think oral isotretinoin ≥0.4 mg/kg/day should be given for ≥3 months to minimize the likelihood of relapse. In addition, we think oral isotretinoin monotherapy should be considered a promising treatment alternative for FD that warrants further research. © 2017 The International Society of Dermatology.
  • No Thumbnail Available
    Item
    Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study
    (Lippincott Williams and Wilkins, 2020) Asçibasi K.; Çökmüs F.P.; Dikici D.S.; Özkan H.M.; Alçi D.; Altunsoy N.; Kuru E.; Yüzeren S.; Aydemir Ö.
    Purpose/Background Emotional adverse effects due to antidepressant use may cause difficulties for the clinician in the treatment of depression. In this prospective study, the emotional adverse effects of antidepressants were evaluated in various aspects. Methods/Procedures Ninety eight patients diagnosed with major depressive disorder were included in the study. At 2nd, 4th, 8th, 12th, and 16th weeks, patients were assessed with Montgomery-Asberg Depression Rating Scale (MADRS), and the antidepressant dose was increased in patients with less than a 50% reduction at each visit compared with the initial MADRS score. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQESA) was used at the 8th-week and 16th-week visits. Findings/Results A significant difference is found in the OQESA score at the 8th-week visit compared with the 16th-week assessment (P < 0.001, t = 5.73). There were significant correlations between MADRS scores and OQESA scores both at the 8th (r = 0.346, P = 0.05) and the 16th (r = 0.490, P < 0.001) weeks. In regression analyses, at eighth-week assessment, MADRS score (B = 1.487, P = 0.002) and selective serotonin reuptake inhibitor use (B = 14.014, P = 0.023) had a significantly predicted OQESA score. Implications/Conclusions In this study, it is found that, as the rate of remitted patients is increased, OQESA scores get decreased, and furthermore, the OQESA score of the remitted group is statistically low when compared with that of the nonremitted group at the 8th- and 16th-week visits. Oxford Questionnaire on the Emotional Side-effects of Antidepressants and MADRS scores are significantly correlated in all assessments. These results suggest that the score obtained from OQESA may be related not only to the emotional adverse effects of antidepressants but also to the residual symptoms of depression. © Wolters Kluwer Health, Inc. All rights reserved.